BioSpace News Archive

Transparency Market Research has published a new report titled, “Drug Eluting Balloon Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. According to the report, the global drug eluting balloon market was valued at US$ 420 Mn in 2017 and is expected to reach US$ 1800 Mn in 2026, expanding at a CAGR of around 18% from 2018 to 2026.

The demand within the global market for bovine respiratory disease treatment has been rising on account of advancements in the field of pulmonary disease treatment, finds TMR.

Lupin Pharmaceuticals Inc., the U.S. based wholly-owned subsidiary of Lupin Limited, and PlushCare, a leading virtual doctor’s appointment service, announced an agreement to allow treatment for bacterial vaginosis in adult women, via the PlushCare virtual platform.

The global digital blood pressure monitors market is projected to gain stupendous amount in the form of revenues during the forecast period of 2019 to 2929, states the recently published report by TMR Research.

Emerald Health Therapeutics, Inc. announced that, further to its news release on April 29th, Emerald will report its financial results for the first quarter ended March 31, 2020, after the market close on Thursday, June 18, 2020.

Medicenna Therapeutics Corp., a clinical stage immuno-oncology company, announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medicenna, will present a corporate overview at the Raymond James 2020 Human Healthcare Innovation Conference on Thursday, June 18th, 2020, at 1:40 PM ET.

Deciphera Pharmaceuticals, Inc. announced that Tucker Kelly, Executive Vice President, Chief Financial Officer and Treasurer, will present at the JMP Securities Hematology and Oncology Forum on Thursday, June 18, 2020 at 2:40 PM ET.

Growth & Emerging Markets Business Unit increasing focus on innovative medicines for complex and rare diseases

Collaboration focuses on clinical development of MGTA-145 for stem cell mobilization in allogeneic transplant in patients with blood cancers

Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that David A. Weber, Ph.D., president and chief executive officer, is scheduled to present a company overview at the Raymond James 2020 Human Health Innovation Conference